
Keywords: Hepatocellular carcinoma; Personalized medicine; Sorafenib; Biomarkers; Molecular marker based-therapy; Individualized therapy; HCC; hepatocellular carcinoma; ICC; intrahepatic cholangiocarcinoma; PCNA; proliferating cell nuclear antigen; CIN; chromosomal